

**APB527Hu01 2mg**  
**Active Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9)**  
**Organism Species: Homo sapiens (Human)**  
***Instruction manual***

FOR RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

13th Edition (Revised in Aug, 2023)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Asn40~Glu153

**Tags:** N-terminal His-tag

**Purity:** >98%

**Endotoxin Level:** <1.0EU per 1µg (determined by the LAL method).

**Buffer Formulation:** PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.

**Original Concentration:** 800µg/mL

**Applications:** Cell culture; Activity Assays; In vivo assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 8.3

**Predicted Molecular Mass:** 13.6kDa

**Accurate Molecular Mass:** 16kDa as determined by SDS-PAGE reducing conditions.

## **[ USAGE ]**

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

## **[ SEQUENCE ]**

N RNQICSPCPP  
NSFSSAGGQR TCDICRQCKG VFRTRKECSS TSNAECDCTP GFHCLGAGCS  
MCEQDCKQGQ ELTKKGCKDC CFGTFNDQKR GICRPWTNCS LDGKSVLVNG  
TKE

## **[ ACTIVITY ]**

TNFRSF9 (Tumor necrosis factor receptor superfamily member 9) is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. A binding ELISA assay was conducted to detect the interaction of TNFRSF9 and TNFa. Briefly, recombinant human TNFRSF9 were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to TNFa-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-TNFRSF9 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF9 and TNFa was shown in Figure 1, and this effect was in a dose dependent manner.




Figure 1. The binding activity of TNFRSF9 with TNF $\alpha$ .

## [ IDENTIFICATION ]




Figure 2. SDS-PAGE

Sample: Active recombinant TNFRSF9, Human

## [ IMPORTANT NOTE ]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.



*Cloud-Clone Corp.*